MAY 12, 2020 8:43 PM PDT

Novel Drug Approved for Non-Small Cell Lung Cancer

WRITTEN BY: Nouran Amin

The US Food and Drug Administration (FDA) recently approved a therapeutic for treating metastatic non-small cell lung cancer (NSCLC). The therapeutic called ‘Tabrecta™ (capmatinib, formerly INC280)’ is an oral MET inhibitor for patients with a METex14 mutation in their tumors.

Learn more about non-small cell lung cancer (NSCLC):

 

 

“Non-small cell lung cancer is a complex disease, with many different possible mutations that may encourage the cancer’s growth,” said Juergen Wolf, MD, from the Center for Integrated Oncology, University Hospital Cologne and lead investigator of the GEOMETRY study. “MET exon 14 skipping is a known oncogenic driver. With today’s decision by the FDA, we can now test for and treat this challenging form of lung cancer with targeted therapy, offering new hope for patients with NSCLC harboring this type of mutation.”

The approval of Trabecta is based on findings from the pivotal GEOMETRY mono-1 Phase II clinical trial. The most common side-effects noted were peripheral edema, nausea, fatigue, vomiting, dyspnea, and decreased appetite.

“Today, and especially during these difficult times, we are incredibly proud that Tabrecta is the first treatment approved by the FDA specifically to treat patients diagnosed with this aggressive NSCLC associated with METex14,” said Susanne Schaffert, PhD, President, Novartis Oncology. “In our quest to reimagine medicine, we have worked tirelessly over the past decades to advance the understanding and treatment of NSCLC, striving to make a difference in patients’ lives, one mutation at a time. We thank all the physicians, patients and families involved in the Tabrecta clinical trials, and we remain committed to advancing innovative solutions for the patients we work to serve.”

Source: Novartis

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
NOV 22, 2020
Cannabis Sciences
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
NOV 22, 2020
Synthetic Cannabinoids Linked to Increased Deaths in Older Patients with COPD
Researchers from St. Michael’s Hospital in Toronto have found that two synthetic cannabinoids available on prescri ...
NOV 24, 2020
Drug Discovery & Development
MMR Vaccine Shows Promise Against COVID-19
NOV 24, 2020
MMR Vaccine Shows Promise Against COVID-19
Researchers have found that a vaccine used for mumps, measles, and rubella (MMR) may be effective in protecting against ...
NOV 23, 2020
Drug Discovery & Development
Therapeutically Active Ion-Channels
NOV 23, 2020
Therapeutically Active Ion-Channels
Therapeutically relevant ion channels have inspired researchers to look into drugs that can regulate their activity. Ion ...
DEC 15, 2020
Clinical & Molecular DX
Who Should Get the COVID Vaccine First?
DEC 15, 2020
Who Should Get the COVID Vaccine First?
Drug developers’ frantic hunt for vaccines against SARS-CoV-2 has finally begun to bear fruit, with several vaccin ...
JAN 22, 2021
Drug Discovery & Development
Treating NF1: Investigational Drug Shows Positive Results
JAN 22, 2021
Treating NF1: Investigational Drug Shows Positive Results
From preclinical studies, researchers have found that an investigational drug called ‘cabozantinib’ can trea ...
Loading Comments...